Roberto Scicali1, Giuseppe Mandraffino2, Antonino Di Pino1, Michele Scuruchi3, Viviana Ferrara1, Giovanni Squadrito3, Francesco Purrello1, Salvatore Piro1. 1. Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. 2. Department of Clinical and Experimental Medicine, University Hospital "G. Martino", Lipid Center, University of Messina, Messina, Italy. Electronic address: gmandraffino@unime.it. 3. Department of Clinical and Experimental Medicine, University Hospital "G. Martino", Lipid Center, University of Messina, Messina, Italy.
Abstract
BACKGROUND AND AIMS: Neutrophil-to-lymphocyte ratio (NLR) is a novel inflammatory biomarker strongly associated with atherosclerotic cardiovascular disease (ASCVD). Our aim was to evaluate the role of NLR on pulse wave velocity (PWV) after adding-on proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9-i) in familial hypercholesterolemia (FH) subjects with ASCVD. METHODS AND RESULTS: In this prospective observational study, we evaluated 45 FH subjects with ASCVD on high-intensity statins plus ezetimibe and with an off-target LDL-C. Study population was divided into two groups according to the mean value of NLR. All patients received PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i. After six months of add-on PCSK9-i therapy, a significant reduction of TC, LDL-C, Non-HDL-C, Lp(a) and ApoB plasma levels was observed in the two groups; while low-NLR group exhibited a significant PWV reduction after six-month therapy with PCSK9-i (Δ -16.2%, p < 0.05), no significant changes in PWV were observed in the high-NLR group. CONCLUSIONS: Only FH subjects with low-NLR experienced a significant reduction of PWV after PCSK9-i. Our findings suggest a role of NLR in predicting PCSK9-i effect in FH subjects with ASCVD.
BACKGROUND AND AIMS: Neutrophil-to-lymphocyte ratio (NLR) is a novel inflammatory biomarker strongly associated with atherosclerotic cardiovascular disease (ASCVD). Our aim was to evaluate the role of NLR on pulse wave velocity (PWV) after adding-on proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9-i) in familial hypercholesterolemia (FH) subjects with ASCVD. METHODS AND RESULTS: In this prospective observational study, we evaluated 45 FH subjects with ASCVD on high-intensity statins plus ezetimibe and with an off-target LDL-C. Study population was divided into two groups according to the mean value of NLR. All patients received PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i. After six months of add-on PCSK9-i therapy, a significant reduction of TC, LDL-C, Non-HDL-C, Lp(a) and ApoB plasma levels was observed in the two groups; while low-NLR group exhibited a significant PWV reduction after six-month therapy with PCSK9-i (Δ -16.2%, p < 0.05), no significant changes in PWV were observed in the high-NLR group. CONCLUSIONS: Only FH subjects with low-NLR experienced a significant reduction of PWV after PCSK9-i. Our findings suggest a role of NLR in predicting PCSK9-i effect in FH subjects with ASCVD.
Authors: Arianna Toscano; Maria Cinquegrani; Michele Scuruchi; Antonino Di Pino; Salvatore Piro; Viviana Ferrara; Carmela Morace; Alberto Lo Gullo; Egidio Imbalzano; Francesco Purrello; Giovanni Squadrito; Roberto Scicali; Giuseppe Mandraffino Journal: Biomolecules Date: 2022-04-09
Authors: Yuqi Zhu; Gang Li; Jari A Laukkanen; Xing Song; Jing Zhang; Linping Wei; Xinrui Chen; Yufeng Li; Cheng Liu Journal: Front Cardiovasc Med Date: 2022-09-08
Authors: Mateusz Maligłówka; Michał Kosowski; Marcin Hachuła; Marcin Cyrnek; Łukasz Bułdak; Marcin Basiak; Aleksandra Bołdys; Grzegorz Machnik; Rafał Jakub Bułdak; Bogusław Okopień Journal: Metabolites Date: 2022-03-17